{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T03:44:25Z","timestamp":1790567065280,"version":"4.1.0"},"reference-count":48,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Arthritis Care &amp;amp; Research"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>There is no standardized approach to the treatment of pediatric antineutrophil cytoplasmic antibody\u2013associated vasculitis (AAV). Because of the rarity of pediatric AAV, randomized trials have not been feasible. The present study of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) was undertaken to establish consensus treatment plans (CTPs) for severe pediatric AAV to enable the future study of comparative effectiveness and safety.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A workgroup of CARRA members (rheumatologists and nephrologists) formed the AAV Workgroup. This group performed a literature review on existing evidence\u2010based treatments and guidelines for the management of AAV. They determined that the target population for CTP development was patients &lt;18\u2009years of age with new\u2010onset granulomatosis with polyangiitis (GPA), microscopic polyangiitis, or renal\u2010limited AAV (eosinophilic GPA was excluded), with presentation confined to those with severe disease (i.e., organ\u2010 or life\u2010threatening). Face\u2010to\u2010face consensus conferences employed nominal group techniques to identify treatment strategies for remission induction and remission maintenance, data elements to be systematically collected, and outcomes to be measured over time.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The pediatric AAV Workgroup developed 2 CTPs for each of the remission induction and remission maintenance of severe AAV. A glucocorticoid\u2010weaning regimen for induction and maintenance, a core data set, and outcome measures were also defined. A random sample of CARRA membership voted acceptance of the CTPs for remission induction and remission maintenance, with a 94% (75 of 80) and 98% (78 of 80) approval rate, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Consensus methodology established standardized CTPs for treating severe pediatric AAV. These CTPs were in principle accepted by CARRA\u2010wide membership for the evaluation of pragmatic comparative effectiveness in a long\u2010term registry.<\/jats:p><\/jats:sec>","DOI":"10.1002\/acr.24590","type":"journal-article","created":{"date-parts":[[2021,3,6]],"date-time":"2021-03-06T05:01:01Z","timestamp":1615006861000},"page":"1550-1558","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Consensus Treatment Plans for Severe Pediatric Antineutrophil Cytoplasmic Antibody\u2013Associated Vasculitis"],"prefix":"10.1002","volume":"74","author":[{"given":"Kimberly A.","family":"Morishita","sequence":"first","affiliation":[{"name":"British Columbia's Children's Hospital and the University of British Columbia  Vancouver British Columbia Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Wagner\u2010Weiner","sequence":"additional","affiliation":[{"name":"University of Chicago Medical Center  Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7632-6790","authenticated-orcid":false,"given":"Eric Y.","family":"Yen","sequence":"additional","affiliation":[{"name":"University of California  Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vidya","family":"Sivaraman","sequence":"additional","affiliation":[{"name":"Nationwide Children's Hospital and The Ohio State University  Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen E.","family":"James","sequence":"additional","affiliation":[{"name":"University of Utah  Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Gerstbacher","sequence":"additional","affiliation":[{"name":"Stanford University  Stanford California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann M.","family":"Szymanski","sequence":"additional","affiliation":[{"name":"Johns Hopkins All Children's Hospital  Saint Petersburg Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen M.","family":"O'Neil","sequence":"additional","affiliation":[{"name":"Riley Hospital for Children at Indiana University Health  Indianapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Cabral","sequence":"additional","affiliation":[{"name":"British Columbia's Children's Hospital and the University of British Columbia  Vancouver British Columbia Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Childhood Arthritis and Rheumatology Research Alliance (CARRA) Antineutrophil Cytoplasmic Antibody\u2013Associated Vasculitis Workgroup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,6]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.37715"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203927"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209133"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150376"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket445"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2018.05.007"},{"key":"e_1_2_7_8_1","first-page":"224","article-title":"Establishment of a pilot pediatric registry for chronic vasculitis is both essential and feasible: a Childhood Arthritis and Rheumatology Alliance (CARRA) survey","volume":"34","author":"Wilkinson NM","year":"2007","journal-title":"J Rheumatol"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-017-0191-z"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24876"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39729"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40395"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22259"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20695"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23462"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.116624"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200104)44:4<912::AID-ANR148>3.0.CO;2-5"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202111"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41901"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa057"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfx378"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-019-0365-y"},{"issue":"124","key":"e_1_2_7_23_1","first-page":"188","article-title":"Rituximab\u2010associated hypogammaglobulinaemia in ANCA\u2010associated vasculitis and connective tissue diseases: a longitudinal observational study","volume":"38","author":"Padoan R","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-10-200905190-00004"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909169"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909905"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket381"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24637"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39450"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.1658"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1404231"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212768"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-019-1226-0"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2019.105883"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1803537"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-012-2198-5"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.151.3.7881673"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20279"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-013-2293-4"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211796"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212861"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40112"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.062711"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-eular.5893"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.10095"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2018.11.008"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208073"},{"key":"e_1_2_7_48_1","first-page":"10","article-title":"A randomized, controlled trial of rituximab versus azathioprine after induction of remission with rituximab for patients with ANCA\u2010associated vasculitis and relapsing disease","volume":"71","author":"Smith R","year":"2019","journal-title":"Arthritis Rheum"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.08.036"}],"container-title":["Arthritis Care &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr.24590","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/acr.24590","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr.24590","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T14:58:07Z","timestamp":1759417087000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/acr.24590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":48,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["10.1002\/acr.24590"],"URL":"https:\/\/doi.org\/10.1002\/acr.24590","archive":["Portico"],"relation":{},"ISSN":["2151-464X","2151-4658"],"issn-type":[{"value":"2151-464X","type":"print"},{"value":"2151-4658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"2020-10-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}